Goldman Sachs initiated coverage of Grail with a Neutral rating and $60 price target. While the company's Galleri test has had success in penetrating the self-pay market for multi-cancer early detection, there is uncertainty around how the FDA and Centers for Medicare and Medicaid Services will evaluate clinical validity and utility in multi-cancer early detection tests, the analyst tells investors in a research note.
